Selinexor Delays Wild-type TP53 Endometrial Cancer Progression

Abstract

In a phase III trial, taking the XPO1 inhibitor selinexor as maintenance therapy was associated with a significant and durable progression-free survival benefit for women with advanced or recurrent TP53 wild-type endometrial cancer—regardless of microsatellite stability.